Everything below concerns Intranasal route. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-01-18. Numbers and descriptions here follow the published literature rather than marketing material.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. It was designed as a stabilized analogue of tuftsin, a naturally occurring tetrapeptide fragment derived from the immunoglobulin heavy chain. The additional Pro-Gly-Pro segment at the carboxyl terminus is intended to slow enzymatic cleavage. The compound is usually described in the literature as a synthetic peptide with anxiolytic and cognitive-related activity, a label that reflects a research context rather than an approved therapeutic category.
Most published work on selank originates from a small number of research groups in the Russian Federation. A large share of that record appears in Russian-language journals, which limits access for readers who rely on English-indexed databases. Independent replication by laboratories outside the original research network is sparse in publicly available sources. This concentration of origin and language is a frequently noted feature when the compound is summarized in broader reviews of synthetic peptides.
Reported pharmacological effects center on reduced anxiety-like behavior in animal models and on measures of memory and learning. Proposed contributing mechanisms include modulation of GABAergic signaling, shifts in monoamine turnover, and changes in the activity of enzymes that degrade neuropeptides. Effects on the expression of genes linked to neuroplasticity have also been described. No single molecular target is widely accepted, and whether the behavioral findings arise from one pathway or several remains an open question.
Pharmacokinetic data are limited. Like most short peptides, Selank is vulnerable to plasma and tissue peptidases, and its measured half-life in circulation is short, on a minutes scale. The Pro-Gly-Pro tail slows this degradation but does not eliminate it. Intranasal administration is the route described in most reports, with absorption through the nasal mucosa and a hypothesized path into the central nervous system that avoids the blood-brain barrier. Direct measurements of human brain exposure are unavailable, so distribution claims rest on inference from animal work.
Clinical evidence comes mainly from small studies conducted in Russia, several of which were open-label or lacked robust blinding. Reported outcomes include lower anxiety scores, changes in attention measures, and effects on asthenic states following illness. Sample sizes are typically in the tens of participants, and independent replication outside the region is scarce. Reviews published in English generally note the limited methodological quality of the underlying trials. Whether the compound produces clinically meaningful effects under rigorous conditions remains unresolved.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C33H57N11O9 | Derived from the seven-residue sequence |
| Molecular weight | About 751.9 g/mol | Average mass; the monoisotopic value is slightly lower |
| Residue count | Seven amino acids | Thr-Lys-Pro-Arg-Pro-Gly-Pro |
| Parent compound | Tuftsin (Thr-Lys-Pro-Arg) | Selank extends tuftsin at the C-terminus |
| Compound class | Synthetic short peptide | Studied in a research setting; not a licensed drug in most markets |
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, with mass spectrometry used to confirm molecular mass and sequence information. Amino acid analysis and peptide mapping may supplement these methods. Certified reference standards are scarce, and many commercial lots are sold as research chemicals without a pharmacopoeial monograph. Regulatory treatment differs by country: Selank is a registered prescription medicine in Russia, while in the European Union and the United States it is not an approved drug and may fall under research-chemical or unapproved-product frameworks.
Selank is a hydrophilic peptide and dissolves readily in water and in aqueous buffers. The lyophilised powder is typically a white to off-white solid. Because short peptides are prone to hydrolysis and oxidation, handling benefits from limiting exposure to heat, moisture and strong light. Working solutions are commonly prepared in sterile water or saline, and repeated freeze-thaw cycles are avoided to reduce aggregation and loss of activity. These practices reflect general laboratory convention rather than published stability specifications.
Dry powder is normally held at -20 degrees Celsius or lower, in a sealed container with desiccant and protection from light. Reconstituted solutions are usually kept at 2 to 8 degrees Celsius for short periods and frozen for longer ones. Proline residues at several positions are generally associated with some resistance to peptidase attack, but chemical stability still declines at neutral to alkaline pH and at elevated temperature. Exact shelf-life figures are product-specific and are not standardised across suppliers.
Measuring peptide exposure inside the brain is technically difficult. Selank is degraded rapidly in plasma, and assays must separate intact peptide from fragments, which favors targeted mass spectrometry over immunoassays alone. Reported half-lives are short, on the order of minutes, so effects observed hours later are attributed to downstream signaling rather than to the parent compound. Blood-brain barrier permeability is debated and rarely quantified directly. Gaps include absent dose-response characterization, inconsistent reporting of purity, and almost no pharmacokinetic data from human participants.
Selank is studied chiefly as an animal-model anxiolytic with proposed secondary effects on memory and immune signaling. Reported mechanisms include modulation of the GABA-A receptor complex, inhibition of enkephalin-degrading enzymes, and shifts in monoamine turnover within limbic structures. Some experiments describe increased expression of brain-derived neurotrophic factor in the hippocampus after repeated dosing. No single molecular target has been confirmed, and the peptide does not bind any receptor with the selectivity typical of a conventional small-molecule drug. Mechanism therefore remains a set of hypotheses rather than an established pathway.
Solubility behavior is a practical concern for handling. Selank dissolves readily in water and in common aqueous buffers, which simplifies preparation of working solutions. The choice of solvent, ionic strength, and pH can influence aggregation over time, particularly at higher concentrations. Aqueous solutions are typically sterile-filtered before use. Because stability depends on several variables, storage and handling notes should be treated as general guidance rather than fixed rules, and specific values are best confirmed against a certificate of analysis for each batch.
Characterization of Selank in a laboratory setting relies on standard peptide methods. Reverse-phase high-performance liquid chromatography separates the target from related impurities and provides a purity figure, commonly reported as 95 percent or higher. Mass spectrometry, typically electrospray ionization or matrix-assisted laser desorption, confirms the molecular mass and helps detect truncation or modification. Amino acid analysis can verify composition when a sequence-level check is needed. These techniques together establish identity and purity for a given lot.
Lyophilized Selank, the dry powder form, is generally stored frozen at minus 20 degrees Celsius or colder for long-term keeping. The solid is hygroscopic and should stay sealed, dry, and protected from light. Once dissolved, the peptide is less stable and is usually held refrigerated at 2 to 8 degrees Celsius for short periods. Repeated freezing and thawing is avoided because it can promote aggregation and loss of activity. Buffers and pH choice also affect how long a solution remains usable.
=== Taiwan === Ractopamine has been banned in Taiwan since 2006. In the summer of 2007, two US shipments including ractopamine-laced pork were rejected by Taiwan's health authorities, while the Taiwan government had been considering lifting the ban on such imports. This resulted in mass protests in the capital city, Taipei, by swine farmers insisting that the ban remain in place. Health Minister Hou Sheng-mou (侯勝茂) declared no lifting of the ban would occur unless related laws were amended. Although the use of ractopamine in livestock is still banned and enforced on the domestic industry, and the government has maintained a "zero tolerance" policy on pork imports that contain it, Taiwan's legislature amended the food safety act in August 2012 to allow the import of beef products containing up to a maximum residue level of 10 parts per billion of the additive. The remaining restrictions have been an obstacle to the two nations signing a free-trade agreement, and the Office of the United States Trade Representative (USTR)'s 2018 Trade Policy Agenda and 2017 Annual Report assert that these remaining restrictions "...are not based upon science..." and highlights their removal as among the main priorities for the US in its trade with Taiwan. However, Taiwan plans to ease the import restrictions on US pork commencing January 1, 2021
After considering the different sources, it can be concluded that the half-life of vitamin B6 is typically measured in several weeks. The end-product of vitamin B6 catabolism is 4-pyridoxic acid, which makes up about half of the B6 compounds in urine. 4-Pyridoxic acid is formed by the action of aldehyde oxidase in the liver. Amounts excreted increase within 1–2 weeks with vitamin supplementation and decrease as rapidly after supplementation ceases. Other vitamin forms excreted in the urine include pyridoxal, pyridoxamine and pyridoxine, and their phosphates. When large doses of pyridoxine are given orally, the proportion of these other forms increases. A small amount of vitamin B6 is also excreted in the feces. This may be a combination of unabsorbed vitamin and what was synthesized by large intestine microbiota.
Troops decapitated their bodies and displayed their heads along a public road to strike fear into those tempted to accept the Democratic Republic of Vietnam's sovereignty. Massacres did not start with the Americans in My Lai, or the Vietnamese communists in Hue in 1968. And yet, the French Union's massacre of over two hundred Vietnamese women and children in My Tratch in 1948 remains virtually unknown in France to this day. The French Army also utilized torture against Việt Minh prisoners. Benjamin Valentino estimates that the French were responsible for 60,000 to 250,000 civilian deaths.
=== A molecular view going from solution to crystal === Crystal formation requires two steps: nucleation and growth. Nucleation is the initiation step for crystallization. At the nucleation phase, protein molecules in solution come together as aggregates to form a stable solid nucleus. As the nucleus forms, the crystal grows bigger and bigger by molecules attaching to this stable nucleus. The nucleation step is critical for crystal formation since it is the first-order phase transition of samples moving from having a high degree of freedom to obtaining an ordered state (aqueous to solid). For the nucleation step to succeed, the manipulation of crystallization parameters is essential. The approach behind getting a protein to crystallize is to yield a lower solubility of the targeted protein in solution. Once the solubility limit is exceeded and crystals are present, crystallization is accomplished.
Sources: en.wikipedia.org
=== Differential display analysis === Also, a differential display analysis conducted in an erythroleukaemia cell line by Lin and co-researchers discovered that PIDD1 is a direct transcriptional target of p53. Furthermore, PIDD1 overexpression inhibited cell growth by triggering apoptosis in p53-deficient cells, an effect that was reversed when PIDD1 was knocked down. This led to the assumption that PIDD1 plays a critical role in the apoptotic pathway regulated by p53. In p53-deficient HCT116 and HEK293 cells which express the large T antigen, a basal level of PIDD1 expression was observed. This finding suggests that PIDD1 may play roles beyond its traditional involvement in the p53-mediated DNA damage response.
The 1st Infantry Division's Task Force 2–16 Infantry cleared four lanes simultaneously through an enemy fortified trench system while inflicting heavy casualties on Iraqi forces. Task Force 2–16 continued the attack clearing over 21 km (13 mi) of entrenched enemy positions resulting in the capture and destruction of numerous enemy vehicles, equipment, personnel and command bunkers.
ZK-93423 is an anxiolytic drug from the β-carboline family, closely related to abecarnil. It is a nonbenzodiazepine GABAA agonist which is not subtype selective and stimulates α1, α2, α3, and α5-subunit containing GABAA receptors equally. It has anticonvulsant, muscle relaxant and appetite stimulating properties comparable to benzodiazepine drugs. ZK-93423 has also been used as a base to develop new and improved beta-carboline derivatives and help map the binding site of the GABAA receptor.
In November 2019, Bukele's administration began trying to secure a $109 million loan from the Central American Bank for Economic Integration to fund phase three of the Territorial Control Plan. The legislature, which was controlled by ARENA and the FMLN, asked him to give them more time to evaluate the loan. On 6 February 2020, Bukele invoked Article 167 of the country's constitution and called for an emergency meeting of the Legislative Assembly to approve the loan. He called for his supporters to rally around the Legislative Assembly during the emergency meeting that was scheduled for 9 February. Although Bukele ordered 40 soldiers into the Legislative Assembly's meeting room on the day of the meeting to coerce legislators into approving the loan, a quorum was not reached and the loan was not approved. Opposition politicians described the crisis as a "self-coup", and it is known in El Salvador as "9F" or "El Bukelazo". In the 2021 legislative elections, Nuevas Ideas received a supermajority in the Legislative Assembly. On 1 May 2021, Nuevas Ideas formed a coalition government with GANA, the National Coalition Party (PCN), and the Christian Democratic Party (PDC). That day, the coalition voted to remove the five justices of the Supreme Court of Justice's constitutional court and Attorney General Raúl Melara. The justices were replaced by five of Bukele's allies, and Melara was replaced by Rodolfo Delgado.
== Premier computing ecosystem == Throughout its history, LLNL has been an early adopter of computers and scientific computing. Even before the Livermore Lab opened its doors, E.O. Lawrence and Edward Teller emphasized the role of computing and the potential of computational simulation. Their purchase of one of the first UNIVAC computers set the precedent for LLNL's history of acquiring and utilising high performance supercomputers. A succession of increasingly powerful and fast computers have been used at the Lab over the years in support of the stockpile stewardship mission. LLNL researchers also use supercomputers to answer questions about subjects such as materials science simulations, climate change, reactions to natural disasters, and other physical phenomena. LLNL has a long history of developing high performance computing software and systems, focusing on creating highly complex physics models, visualization codes, and other unique applications tailored to specific research requirements. LLNL-developed software projects optimize the operation and management of the computer systems, including operating systems such as NLTSS or TOSS (Tri-Laboratory Operating System Stack), software build and installation tools such as Spack, and resource management packages such as Flux and SLURM. LLNL also initiated and continues leading the development of ZFS on Linux, the official port of ZFS to the Linux operating system.
Sources: en.wikipedia.org
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, designed as a metabolically stabilized analogue of the endogenous tetrapeptide tuftsin. It has been studied mainly against anxiety-related and cognitive endpoints rather than as an approved medicine in most jurisdictions.
Tuftsin contains four residues, while selank carries an additional Pro-Gly-Pro segment at the carboxyl end. That extension is intended to reduce enzymatic cleavage. Comparative pharmacokinetic data in humans remain limited.
No single receptor target is widely accepted as the definitive mediator of the reported effects. Proposed contributors include GABAergic modulation, shifts in monoamine turnover, and altered neuropeptide degradation. The mechanism is treated in the literature as unresolved.
Reports describe effects on GABA-A receptor expression, monoamine turnover, and neurotrophic factor levels. These are proposed mechanisms drawn mainly from animal models. No single molecular target has been established.